Dose-Dependent Differences in the Profile of Mutations Induced by Carcinogenic (R,S,S,R) Bay-and Fjord-Region Diol Epoxides of Polycyclic Aromatic Hydrocarbons

  • Allan H. Conney
  • Richard L. Chang
  • Xiao Xing Cui
  • Maria Schiltz
  • Haruhiko Yagi
  • Donald M. Jerina
  • Shu-Jing C. Wei
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 500)

Abstract

Chinese hamster V79 cells were exposed to a high or low concentration of the highly carcinogenic, (R,S,S,R) or the less active (S,R,R,S) bay-or fjord-region diol epoxides of benzo[a]pyrene, benzo[c]phenanthrene or dibenz[c,h]acridine. Independent 8-azaguanine-resistant clones were isolated, and base substitutions at the hypoxanthine (guanine) phosphoribosyltransferase, (hprt) locus were determined. For the three (R,S,S,R) diol epoxides studied, the proportion of mutations at AT base pairs increased as the concentration of diol epoxide decreased. Concentration-dependent differences in the mutational profile were not observed, however, for the three (S,R,R,S) diol epoxides. In studies, with V-H1 cells (a DNA repair deficient variant of V79 cells), a concentration-dependent difference in the profile of mutations for the (R,S,S,R) diol epoxide of benzo[a]pyrene was not observed. These results suggest that concentration-dependent differences in the mutational profile are dependent on an intact DNA repair system. In additional studies, we initiated mouse skin with a high or low dose of benzo[a]pyrene and promoted the mice for 26 weeks with 12-O-tetradecanoylphorbol-13-acetate. Papillomas were examined for mutations in the c-Ha-ras proto-oncogene. Dose-dependent differences in the profile of c-Ha-ras mutations in the tumors were observed. In summary, (i) dose-dependent differences in mutational profiles at the, hprt locus were observed in Chinese hamster V79 cells treated with several highly mutagenic and carcinogenic (R,S,S,R) bay-or fjord-region diol epoxides but not with their less active (S,R,R,S) diol epoxide enantiomers, (ii) a dose-dependent difference in the mutational profile was not observed for the (R,S,S,R) diol epoxide of benzo[a]pyrene in a DNA-repair defective V79 cell line, and (iii) a dose-dependent difference in the mutational profile in the c-Ha-ras proto-oncogene was observed in tumors from mice treated with a high or low dose of benzo[a]pyrene.

Keywords

Polycyclic Aromatic Hydrocarbon Adduct Epoxide Diol Guanine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S.-J.C. Wei, R.L. Chang, C.Q.,Wong, N. Bhachech, X.X. Cui, E. Hennig, H. Yagi, J.M. Sayer, D.M. Jerina, B.D. Preston, and A.H. Conney, Dose-dependent differences in the profile of mutations induced by an ultimate carcinogen from benzo[a]pyrene, Proc. Natl Acad. Sci. USA 88: 11227–11230 (1991).PubMedCrossRefGoogle Scholar
  2. 2.
    S.-J.C. Wei, R.L. Chang, N. Bhachech, X.X. Cui, K.A. Merkler, C.Q Wong, E. Hennig, H. Yagi, D.M. Jerina, and A.H. Conney, Dose-dependent differences in the profile of mutations induced by (+)-7R,8S-dihydroxy-9S,10R-epoxy-7,8,9,10tetrahydrobenzo[a]pyrene in the coding region of the hypoxanthine (guanine) phosphoribosyltransferase gene in Chinese hamster V79 cells, Cancer Res. 53: 3294–3301 (1993).PubMedGoogle Scholar
  3. 3.
    E. Hennig, A.H. Conney, and S.-J.O. Wei, Characterization of, hprt splicingmutations induced by the ultimate carcinogenic metabolite of benzo[a]pyrene in Chinese hamster V79 cells, Cancer Res. 55: 1550–1558 (1995).Google Scholar
  4. 4.
    S.-J.C. Wei, R.L. Chang, X.X. Cui, K.A. Merkler, C.Q. Wong, H. Yagi, D.M. Jerina, and A.H. Conney, Dose-dependent differences in the mutational profiles of (-)-(1 R,2S,3S,4R)-3,4-dihydroxy-1,2-epoxy-1,2,3,4-tetrahydrobenzo [c]phenanthrene and its less carcinogenic enantiomer, Cancer Res. 56: 3695–3703 (1996).PubMedGoogle Scholar
  5. 5.
    X.X. Cui, R.L. Chang, M. D’Ayala, A. Kolly, S. Kumar, N. Shirai, D. Jerina, R. Lehr, A.H. Conney, and S.C. Wei, Dose dependent difference in mutation profile of (+)-1 R,2S-epoxy-3S,4R-dihydroxy-1,2,3,4-tetrahydrodibenz[c,h]acridine ((+)DB[c,h]AcrDE), Proc. Am. Assoc. Cancer Res. 39: 186 (1998).Google Scholar
  6. 6.
    S-J.C. Wei, R.L. Chang, K.A. Merkler, M.Gwynne, X.X. Cui, B. Murthy, M-T. Huang, J-G. Xie, Y-P. Lu, Y-R. Lou, D.M. Jerina and A.H. Conney, Dose-dependent mutation profile in the c-Ha-ras proto-oncogene of skin tumors in mice initiated with benzo[a]pyrene, Carcinogenesis 20: 1689–1696 (1999).PubMedCrossRefGoogle Scholar
  7. 7.
    T. Meehan and K. Straub, Double-stranded DNA steroselectively binds benzo(a)pyrene diol epoxide, Nature (Lond.) 277: 410–412 (1977)CrossRefGoogle Scholar
  8. 8.
    D.M. Jerina, A. Chadha, A.M. Cheh, M.E. Schurdak, A.W. Wood and J.M. Sayer, Covalent bonding of bay-region diol epoxides to nucleic acids. In: C.M. Witmer, R. Snyder, D.J. Jollow, G.F. Kalf, J.J. Kocsis and I.G. Sipes (eds), Biological Reactive Intermediates IV. Molecular and Cellular Effects and Their Impact on Human Health, pp. 533–553. New York: Plenum Publishing Corp. (1991).Google Scholar
  9. 9.
    M. Schiltz, X.X. Cui, Y-P. Lu, H. Yagi, D.M. Jerina, M.Z. Zdzienicka, R.L. Chang, A.H. Conney and S-J.C. Wei, Characterization of the mutational profile of (+)-7R,8S-dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene at the hypoxanthine (guanine) phosphoribosyltransferase gene in repair-deficient Chinese hamster V-H1 cells, Carcinogenesis 20: 2279–2285 (1999).PubMedCrossRefGoogle Scholar
  10. 10.
    J. Chen and W.G. Tilly, Mutational spectra vary with exposure conditions: benzo[a]pyrene in human cells, Mutat. Res. 357: 209–217 (1996).PubMedCrossRefGoogle Scholar
  11. 11.
    S-J.C. Wei, R.L. Chang, E. Hennig, X.X. Cui, K.A. Merkler, C-Q. Wong, H. Yagi, D.M. Jerina and A.H. Conney, Mutagenic selectivity at the, HPRT locus in V-79 cells: comparison of mutations caused by bay-region benzo[a]pyrene 7,8diol-9,10-epoxide enantiomers with high and low carcinogenic activity, Carcinogenesis 15: 1729–1735 (1994).PubMedCrossRefGoogle Scholar
  12. 12.
    S.K. Agarwal, J.M. Sayer, H.J.C. Yeh, L.K. Pannell, B.D. Hilton, M.A. Pigott, A. Dipple, H. Yagi and D.M. Jerina, Chemical characterization of DNA adducts derived from the configurationally isomeric benzo(c)phenanthrene-3,4-diol 1,2epoxides, J. Am. Chem. Soc. 109: 2497–2504 (1987).CrossRefGoogle Scholar
  13. 13.
    S-J.C. Wei, R.L. Chang, C-Q. Wong, X.X. Cui, N. Dandamudi, Y-P. Lu, K.A. Merkler, J.M. Sayer, A.H. Conney and D.M. Jerina, The ratio of deoxyadenosine to deoxyguanosine adducts formed by (+)-(7R,8S,9S,IOR)-7,8-dihydroxy-9,10epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in purified calf thymus DNA and DNA in V-79 cells is independent of dose, Int. J. Oncol. 14: 509–513 (1999).PubMedGoogle Scholar
  14. 14.
    M.Z. Zdzienicka and J.W.I.M. Simons, Mutagen-sensitive cell lines are obtained with a high frequency in V79 Chinese hamster cells, Mutat. Res. 178: 235–244 (1987).PubMedCrossRefGoogle Scholar
  15. 15.
    A.R. Collins, Mutant rodent cell lines sensitive to ultraviolet light, ionizing radiation and cross-linking agents: a comprehensive survey of genetic and biochemical characteristics, Mutat. Res., DNA repair 293: 99–118 (1993).CrossRefGoogle Scholar
  16. 16.
    S. Kadkhodayan, E.P. Salazar, M.J. Ramsey, K. Takayama, M. Zdzienicka, J.D. Tucker, and C.A. Weber, Molecular analysis of, ERCC2 mutations in the repair deficient hamster mutants UVL-1 and V-H1, Mutat. Res. 385: 47–57 (1997).PubMedCrossRefGoogle Scholar
  17. 17.
    J.H.J. Hoeijmakers, J-M. Egly, and W. Vermeulen, TFIIH: a key component in multiple DNA transactions, Curr. Opin. Genet. Dey. 6: 26–33 (1996).CrossRefGoogle Scholar
  18. 18.
    D.L. Mitchell, M.Z. Zdzienicka, A.A. van Zeeland, and R.S. Nairn, Intermediate (6–4) photoproduct repair in Chinese hamster V79 mutant V-H1 correlates with intermediate levels of DNA incision and repair replication, Mutat. Res. 226: 4347 (1989).CrossRefGoogle Scholar
  19. 19.
    H. Vrieling, M.L. Van Rooijen, N.A. Groen, M.Z. Zdzienicka, J.W.I.M. Simons, P.H.M. Lohman, and A.A. van Zeeland, DNA strand specificity for UV-induced mutations in mammalian cells., Mol. Cell. Biol. 9: 1277–1283 (1989).PubMedGoogle Scholar
  20. 20.
    D.R. Lloyd and P.C. Hanawalt, p53-dependent global genomic repair of benzo[a]pyrene-7,8-dio1–9,10-epoxide adducts in human cells, Cancer Res. 60: 517–521 (2000).PubMedGoogle Scholar
  21. 21.
    Z.A. Ronai, S. Gradia, K. E1-Bayoumy, S. Amin, S.S. Hecht, Contrasting incidence of, ras mutations in rat mammary and mouse skin tumors induced by anti-benzo[c]phenanthrene-3,4-dio1–1,2-epoxide, Carcinogenesis 14: 2113–2116 (1994).CrossRefGoogle Scholar
  22. 22.
    B. Chen, L. Liu, A. Castonguay, R.R. Maronpot, M.W. Anderson and M. You, Dose-dependent, ras mutation spectra in N-nitrosodiethylamine induced mouse liver tumors and 4-(methylnitrosamino-1-(3-pyridyl)-1-butanone induced mouse lung tumors, Carcinogenesis 14: 1603–1608 (1993).PubMedCrossRefGoogle Scholar
  23. 23.
    S.A. Belinsky, T.R. Devereux, R.R. Maronpot, G.D. Stoner, and M.W. Anderson, Relationship between the formation of promutagenic adducts and the activation of the K ras protooncogene in lung tumors from, A/J mice treated with nitrosamines., Cancer Res. 49: 5305–5311 (1989).PubMedGoogle Scholar
  24. 24.
    S. Manam, G.A. Shinder, D.J. Joslyn, A.R. Kraynak, C.L. Hammermeister, K.R. Leander, B.J. Ledwith, S. Prahalada, M.J. van Zwieten, and W.W. Nichols, Dose-related changes in the profile of ras mutations in chemically induced CD-1 mouse liver tumors, Carcinogenesis 16: 1113–1119 (1995).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Allan H. Conney
    • 1
  • Richard L. Chang
    • 1
  • Xiao Xing Cui
    • 1
  • Maria Schiltz
    • 1
  • Haruhiko Yagi
    • 1
  • Donald M. Jerina
    • 2
  • Shu-Jing C. Wei
    • 1
  1. 1.Laboratory for Cancer Research, Department of Chemical BiologyCollege of Pharmacy, Rutgers, The State University of New JerseyPiscatawayUSA
  2. 2.Section on Oxidation Mechanisms, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of HealthBethesdaUSA

Personalised recommendations